Zellweger-Like Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders.
|
9683594 |
1998 |
Zellweger-Like Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities.
|
26319495 |
2015 |
Zellweger-Like Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Phenotype-genotype relationships in PEX10-deficient peroxisome biogenesis disorder patients.
|
10862081 |
2000 |
Zellweger-Like Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in PEX10 is the cause of Zellweger peroxisome deficiency syndrome of complementation group B.
|
9700193 |
1998 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
CTD_human |
Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities.
|
26319495 |
2015 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
CTD_human |
All four PEX10-deficient Zellweger Syndrome (ZS) patients were found to have nonsense, frameshift, or splice site mutations that remove large portions of the PEX10 coding region.
|
10862081 |
2000 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
CTD_human |
Mutations in PEX10 is the cause of Zellweger peroxisome deficiency syndrome of complementation group B.
|
9700193 |
1998 |
Zellweger Syndrome
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Peroxisome biogenesis factor 10 (PEX10) is involved in the import of peroxisomal matrix proteins, and the mutation of this gene causes 3 subtypes of peroxisome biogenesis disorders, namely Zellweger syndrome (severe), neonatal adrenoleukodystrophy (moderate) and an ataxic form (mild).
|
28320181 |
2017 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
BEFREE |
All four PEX10-deficient Zellweger Syndrome (ZS) patients were found to have nonsense, frameshift, or splice site mutations that remove large portions of the PEX10 coding region.
|
10862081 |
2000 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
CTD_human |
A Zellweger syndrome patient, PBD100, was homozygous for a splice donor-site mutation that results in exon skipping and loss of 407 bp from the PEX10 open reading frame.
|
9683594 |
1998 |
Zellweger Syndrome
|
0.520 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies.
|
25655951 |
2015 |
Zellweger Spectrum
|
0.310 |
Biomarker
|
disease |
CTD_human |
Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders.
|
9683594 |
1998 |
Zellweger Spectrum
|
0.310 |
Biomarker
|
disease |
CTD_human |
Primary skin fibroblasts from seven PBD-ZSD patients with biallelic PEX1, PEX10, PEX12, or PEX26 mutations and three healthy donors were transduced with retroviral vectors expressing Yamanaka reprogramming factors.
|
26319495 |
2015 |
Zellweger Spectrum
|
0.310 |
Biomarker
|
disease |
CTD_human |
Phenotype-genotype relationships in PEX10-deficient peroxisome biogenesis disorder patients.
|
10862081 |
2000 |
Zellweger Spectrum
|
0.310 |
Biomarker
|
disease |
CTD_human |
Mutations in PEX10 is the cause of Zellweger peroxisome deficiency syndrome of complementation group B.
|
9700193 |
1998 |
Zellweger Spectrum
|
0.310 |
Biomarker
|
disease |
BEFREE |
PBDs include Zellweger spectrum disorders (ZSDs) with a relatively mild clinical phenotype caused by PEX1, (MIM# 602136), PEX2 (MIM# 170993), PEX6 (MIM# 601498), PEX10 (MIM# 602859), PEX12 (MIM# 601758), and PEX16 (MIM# 603360) mutations.
|
27230853 |
2016 |
Wide anterior fontanel
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Visual Impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Visual field constriction
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Very long chain fatty acid accumulation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Ventricular Septal Defects
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Variable expressivity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Upward slant of palpebral fissure
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Underdeveloped supraorbital ridges
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Thickened nuchal skin fold
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|